Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.

Cohen EEW, Soulières D, Swaby RF, Harrington KJ.

Lancet. 2019 Oct 12;394(10206):1323. doi: 10.1016/S0140-6736(19)31264-4. No abstract available.

PMID:
31609223
2.

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. No abstract available.

PMID:
31603413
3.

Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.

Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30258-7. doi: 10.1016/j.clgc.2019.08.009. [Epub ahead of print]

PMID:
31515197
4.

Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis.

Mazzone E, Knipper S, Mistretta FA, Tian Z, Palumbo C, Soulieres D, De Cobelli O, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

World J Urol. 2019 Aug 28. doi: 10.1007/s00345-019-02927-z. [Epub ahead of print]

PMID:
31463562
5.

Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.

Hamilou Z, North S, Canil C, Wood L, Hotte S, Sridhar S, Soulières D, Latour M, Taussky D, Kassouf W, Blais N.

Can Urol Assoc J. 2019 Jul 23. doi: 10.5489/cuaj.5946. [Epub ahead of print] Review. No abstract available.

PMID:
31348743
6.

Renal cell carcinoma in the Canadian Indigenous population.

Wong ECL, Breau RH, Mallick R, Wood L, Pouliot F, Basappa NS, Tanguay S, Soulières D, So A, Heng D, Lavallée LT, Drachenberg D, Kapoor A.

Curr Oncol. 2019 Jun;26(3):e367-e371. doi: 10.3747/co.26.4707. Epub 2019 Jun 1.

7.

Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis.

Nazzani S, Preisser F, Bandini M, Marchioni M, Tian Z, Soulières D, Montanari E, Ratti D, Acquati P, Briganti A, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI.

Eur Urol Oncol. 2018 Sep;1(4):346-351. doi: 10.1016/j.euo.2018.05.008. Epub 2018 May 31.

PMID:
31100257
8.

Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma.

Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Jun;17(3):e602-e611. doi: 10.1016/j.clgc.2019.03.003. Epub 2019 Mar 29.

PMID:
31005472
9.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D.

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

10.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
11.

Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.

Mazzone E, Nazzani S, Knipper S, Tian Z, Preisser F, Gallina A, Soulières D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI.

Eur J Surg Oncol. 2019 Jul;45(7):1253-1259. doi: 10.1016/j.ejso.2019.01.218. Epub 2019 Feb 3.

PMID:
30755341
12.

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS.

Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14.

13.

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Soulières D, Guertin L, Filion E, Christopoulos A, Lambert L, Tehfe M, Ayad T, Charpentier D, Jamal R, Wong P.

BMC Cancer. 2019 Jan 14;19(1):68. doi: 10.1186/s12885-019-5266-4.

14.

Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason G, Heng D, Soulières D, Reaume N, Basappa N, Lévesque E, Dragomir A.

Curr Oncol. 2018 Dec;25(6):e576-e584. doi: 10.3747/co.25.4103. Epub 2018 Dec 1.

15.

Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study.

Laprise C, Madathil SA, Schlecht NF, Castonguay G, Soulières D, Nguyen-Tan PF, Allison P, Coutlée F, Hier M, Rousseau MC, Franco EL, Nicolau B.

Head Neck. 2019 Mar;41(3):678-685. doi: 10.1002/hed.25436. Epub 2019 Jan 3.

PMID:
30605251
16.

Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?

Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI.

Cancer Epidemiol. 2019 Feb;58:83-88. doi: 10.1016/j.canep.2018.11.007. Epub 2018 Dec 6.

PMID:
30528834
17.

More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder.

Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Apr;17(2):105-113.e2. doi: 10.1016/j.clgc.2018.11.003. Epub 2018 Nov 17.

PMID:
30527745
18.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Erratum in: Lancet. 2019 Jan 12;393(10167):132.

PMID:
30509740
19.

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.

Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Br J Cancer. 2018 Dec;119(12):1552-1556. doi: 10.1038/s41416-018-0323-3. Epub 2018 Nov 14.

PMID:
30425350
20.

Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma.

Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, Shariat SF, Soulières D, Montanari E, Acquati P, Briganti A, Carmignani L, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Feb;17(1):e97-e103. doi: 10.1016/j.clgc.2018.09.017. Epub 2018 Sep 27.

PMID:
30337106
21.

The effect of race on survival after local therapy in metastatic prostate cancer patients.

Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz PI.

Can Urol Assoc J. 2019 Jun;13(6):175-181. doi: 10.5489/cuaj.5399.

22.

Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract.

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI.

World J Urol. 2019 Jul;37(7):1329-1337. doi: 10.1007/s00345-018-2516-z. Epub 2018 Oct 8.

PMID:
30298285
23.

Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Soulières D, Reaume MN, Basappa N, Lévesque E, Dragomir A.

Clin Drug Investig. 2018 Dec;38(12):1155-1165. doi: 10.1007/s40261-018-0705-6.

PMID:
30267257
24.

Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis.

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulières D, Montanari E, Acquati P, Briganti A, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI.

Eur Urol Focus. 2018 Sep 25. pii: S2405-4569(18)30279-7. doi: 10.1016/j.euf.2018.09.007. [Epub ahead of print]

PMID:
30266210
25.

Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.

Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Oct;16(5):376-384.e1. doi: 10.1016/j.clgc.2018.05.016. Epub 2018 Jun 5.

PMID:
29954690
26.

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

27.

A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma.

Nazzani S, Bandini M, Marchioni M, Preisser F, Tian Z, Soulières D, Montanari E, Motta G, Acquati P, Briganti A, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI.

Radiother Oncol. 2018 May;127(2):318-325. doi: 10.1016/j.radonc.2018.03.027. Epub 2018 Apr 6.

PMID:
29631934
28.

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.

Acero Brand FZ, Suter N, Adam JP, Faulques B, Maietta A, Soulières D, Blais N.

J Immunother Cancer. 2018 Mar 16;6(1):22. doi: 10.1186/s40425-018-0332-z.

29.

Liver Iron Quantification with MR Imaging: A Primer for Radiologists.

Labranche R, Gilbert G, Cerny M, Vu KN, Soulières D, Olivié D, Billiard JS, Yokoo T, Tang A.

Radiographics. 2018 Mar-Apr;38(2):392-412. doi: 10.1148/rg.2018170079. Review.

PMID:
29528818
30.

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.

Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S.

Clin Cancer Res. 2018 Jun 1;24(11):2505-2516. doi: 10.1158/1078-0432.CCR-17-2644. Epub 2018 Feb 28.

31.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769. No abstract available.

32.

Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol.

Farsi NJ, Rousseau MC, Schlecht N, Castonguay G, Allison P, Nguyen-Tan PF, Souliéres D, Coutlée F, Hier M, Madathil S, Franco EL, Nicolau B.

Carcinogenesis. 2017 Dec 7;38(12):1188-1195. doi: 10.1093/carcin/bgx106.

PMID:
29029021
33.

Four PTEN-targeting co-expressed miRNAs and ACTN4- targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue.

Berania I, Cardin GB, Clément I, Guertin L, Ayad T, Bissada E, Nguyen-Tan PF, Filion E, Guilmette J, Gologan O, Soulieres D, Rodier F, Wong P, Christopoulos A.

Int J Cancer. 2017 Dec 1;141(11):2318-2328. doi: 10.1002/ijc.30915. Epub 2017 Aug 18.

34.

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH.

J Cancer Educ. 2019 Feb;34(1):14-18. doi: 10.1007/s13187-017-1259-7.

PMID:
28779441
35.

A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer.

Taussky D, Souliéres D, Azoulay L, Yin H, Bahig H, Bahary JP, Delouya G.

Target Oncol. 2017 Oct;12(5):695-701. doi: 10.1007/s11523-017-0516-3.

PMID:
28712059
36.

Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study.

Laprise C, Madathil SA, Schlecht NF, Castonguay G, Soulières D, Nguyen-Tan PF, Allison P, Coutlée F, Hier M, Rousseau MC, Franco EL, Nicolau B.

Oral Oncol. 2017 Jun;69:56-61. doi: 10.1016/j.oraloncology.2017.03.013. Epub 2017 Apr 10.

PMID:
28559021
37.

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.

38.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.

Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE.

Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15.

PMID:
28504033
39.

Malignant Rhabdoid Tumor of Soft Tissue.

Guilmette J, Laverdière C, Soulières D, Patey N, Soucy G, Trudel D, Bouron-Dal Soglio D.

Pediatr Dev Pathol. 2017 Jun;20(3):262-266. doi: 10.1177/1093526617706814. Epub 2017 Apr 21.

PMID:
28429647
40.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L.

Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26.

PMID:
28131786
41.

Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.

Vincent MD, Breadner D, Soulieres D, Kerr IG, Sanatani M, Kocha W, Klimo P, MacKenzie MJ, O'Connell A, Whiston F, Malpage AS, Stitt L, Welch SA.

Future Oncol. 2017 Apr;13(9):777-786. doi: 10.2217/fon-2016-0444. Epub 2017 Jan 3.

PMID:
28045335
42.

ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer.

Moecks J, Soulières D, Klughammer B.

J Pathol Clin Res. 2015 Apr 2;1(3):134-43. doi: 10.1002/cjp2.15. eCollection 2015 Jul.

43.

Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129.

Galloway TJ, Zhang QE, Nguyen-Tan PF, Rosenthal DI, Soulieres D, Fortin A, Silverman CL, Daly ME, Ridge JA, Hammond JA, Le QT.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):362-371. doi: 10.1016/j.ijrobp.2016.05.026. Epub 2016 May 28.

44.

The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.

Gaudreau PO, Stagg J, Soulières D, Saad F.

Biomark Cancer. 2016 May 5;8(Suppl 2):15-33. doi: 10.4137/BIC.S31802. eCollection 2016. Review.

45.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.

BMC Cancer. 2016 Jan 15;16:22. doi: 10.1186/s12885-016-2051-5.

46.

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.

Soulières D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang SC, Chin S, Adkins D.

BMC Cancer. 2016 Jan 14;16:19. doi: 10.1186/s12885-016-2064-0.

47.

Neutrophil count is associated with survival in localized prostate cancer.

Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, Soulieres D.

BMC Cancer. 2015 Aug 21;15:594. doi: 10.1186/s12885-015-1599-9.

48.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.

Soulières D, Hirsch FR, Shepherd FA, Bordogna W, Delmar P, Shames DS, Klughammer B.

J Thorac Oncol. 2015 Sep;10(9):1364-1369. doi: 10.1097/JTO.0000000000000624.

49.

Reply to B. O'Sullivan et Al.

Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar AK, Garden AS, Soulieres D, Trotti A, Avizonis VN, Ridge JA, Harris J, Le QT, Gillison M.

J Clin Oncol. 2015 May 20;33(15):1708-9. doi: 10.1200/JCO.2014.60.3555. Epub 2015 Mar 30. No abstract available.

PMID:
25823732
50.

Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer.

Bahig H, Fortin B, Alizadeh M, Lambert L, Filion E, Guertin L, Ayad T, Christopoulos A, Bissada E, Soulières D, Gaba Idiamey F, Nguyen-Tan PF.

Oral Oncol. 2015 May;51(5):521-8. doi: 10.1016/j.oraloncology.2015.02.097. Epub 2015 Mar 18.

PMID:
25797461

Supplemental Content

Loading ...
Support Center